International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 15-25 , 1 January 2006

Combining radiotherapy and angiogenesis inhibitors: Clinical trial design

  • Deborah Citrin, M.D.

      Affiliations

    • Radiation Oncology Branch, NCI, Bethesda, MD
    • Corresponding Author InformationReprint requests to: Deborah Citrin, M.D., Radiation Oncology Branch, NCI, Bldg. 10, Rm. B2-3561, 10 Center Drive, MSC 1682, Bethesda, MD 20892. Tel: (301) 496-5457; Fax: (301) 480-5438
    • ,
  • Cynthia Ménard, M.D.

      Affiliations

    • Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    • ,
  • Kevin Camphausen, M.D.

      Affiliations

    • Radiation Oncology Branch, NCI, Bethesda, MD

Received 1 March 2005 ,Revised 30 March 2005 ,Accepted 31 March 2005.

References 

  1. Ausprunk DH , Folkman J . Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis . Microvasc Res . 1977;14:53–65
  2. Folkman J . How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture . Cancer Res . 1986;46:467–473
  3. Hahnfeldt P , Panigrahy D , Folkman J , et al.   Tumor development under angiogenic signaling (A dynamical theory of tumor growth, treatment response, and postvascular dormancy) . Cancer Res . 1999;59:4770–4775
  4. Hashizume H , Baluk P , Morikawa S , et al.   Openings between defective endothelial cells explain tumor vessel leakiness . Am J Pathol . 2000;156:1363–1380
  5. Morikawa S , Baluk P , Kaidoh T , et al.   Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors . Am J Pathol . 2002;160:985–1000
  6. Jain RK , Munn LL , Fukumura D . Dissecting tumour pathophysiology using intravital microscopy . Nat Rev Cancer . 2002;2:266–276
  7. Jain RK . Determinants of tumor blood flow (A review) . Cancer Res . 1988;48:2641–2658
  8. Tufto I , Rofstad EK . Transient perfusion in human melanoma xenografts . Br J Cancer . 1995;71:789–793
  9. Durand RE , LePard NE . Contribution of transient blood flow to tumour hypoxia in mice . Acta Oncol . 1995;34:317–323
  10. Chaplin DJ , Olive PL , Durand RE . Intermittent blood flow in a murine tumor (radiobiological effects) . Cancer Res . 1987;47:597–601
  11. Chaplin DJ , Durand RE , Olive PL . Acute hypoxia in tumors (Implications for modifiers of radiation effects) . Int J Radiat Oncol Biol Phys . 1986;12:1279–1282
  12. Bussink J , Kaanders JH , van der Kogel AJ . Tumor hypoxia at the micro-regional level (Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers) . Radiother Oncol . 2003;67:3–15
  13. Hall E . Radiobiology for the radiologist . 5th ed.. Philadelphia: Lippincott, Williams & Wilkins; 2000;
  14. Teicher BA , Holden SA , Ara G , et al.   Influence of an anti-angiogenic treatment on 9L gliosarcoma (Oxygenation and response to cytotoxic therapy) . Int J Cancer . 1995;61:732–737
  15. Lee CG , Heijn M , di Tomaso E , et al.   Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions . Cancer Res . 2000;60:5565–5570
  16. Griffin RJ , Williams BW , Wild R , et al.   Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response . Cancer Res . 2002;62:1702–1706
  17. Teicher BA , Holden SA , Ara G , et al.   Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents . Int J Cancer . 1994;57:920–925
  18. Wachsberger P , Burd R , Dicker AP . Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents (Exploring mechanisms of interaction) . Clin Cancer Res . 2003;9:1957–1971
  19. O’Reilly MS , Holmgren L , Chen C , et al.   Angiostatin induces and sustains dormancy of human primary tumors in mice . Nat Med . 1996;2:689–692
  20. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy (A new paradigm for combination therapy) . Nat Med . 2001;7:987–989
  21. Tong RT , Boucher Y , Kozin SV , et al.   Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors . Cancer Res . 2004;64:3731–3736
  22. Yuan F , Chen Y , Dellian M , et al.   Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody . Proc Natl Acad Sci USA . 1996;93:14765–14770
  23. Folkman J , Camphausen K . Cancer (What does radiotherapy do to endothelial cells?) . Science . 2001;293:227–228
  24. Gorski DH , Beckett MA , Jaskowiak NT , et al.   Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation . Cancer Res . 1999;59:3374–3378
  25. Geng L , Donnelly E , McMahon G , et al.   Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy . Cancer Res . 2001;61:2413–2419
  26. Shaheen RM , Tseng WW , Davis DW , et al.   Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms . Cancer Res . 2001;61:1464–1468
  27. Ruegg C , Meuwly JY , Driscoll R , et al.   The quest for surrogate markers of angiogenesis (A paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials) . Curr Mol Med . 2003;3:673–691
  28. Boehm T , Folkman J , Browder T , et al.   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance . Nature . 1997;390:404–407
  29. Drevs J , Laus C , Mendinger M , et al.   Antiangiogenesis (Current clinical data and future perspectives) . Onkologie . 2002;25:520–527
  30. Kerbel RS , Yu J , Tran J , et al.   Possible mechanisms of acquired resistance to anti-angiogenic drugs (Implications for the use of combination therapy approaches) . Cancer Metast Rev . 2001;20:79–86
  31. Yu JL , Rak JW , Coomber BL , et al.   Effect of p53 status on tumor response to antiangiogenic therapy . Science . 2002;295:1526–1528
  32. Richard DE , Berra E , Pouyssegur J . Angiogenesis (How a tumor adapts to hypoxia) . Biochem Biophys Res Commun . 1999;266:718–722
  33. Koukourakis MI , Giatromanolaki A , Sivridis E , et al.   Squamous cell head and neck cancer (Evidence of angiogenic regeneration during radiotherapy) . Anticancer Res . 2001;21:4301–4309
  34. Katoh O , Tauchi H , Kawaishi K , et al.   Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation . Cancer Res . 1995;55:5687–5692
  35. Gupta VK , Jaskowiak NT , Beckett MA , et al.   Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance . Cancer J . 2002;8:47–54
  36. Kumar P , Miller AI , Polverini PJ . p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway . J Biol Chem . 2004;279:43352–43360
  37. Smith BD , Smith GL , Carter D , et al.   Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma . J Clin Oncol . 2000;18:2046–2052
  38. Linderholm B , Grankvist K , Wilking N , et al.   Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment . J Clin Oncol . 2000;18:1423–1431
  39. Jameel JK , Rao VS , Cawkwell L , et al.   Radioresistance in carcinoma of the breast . Breast . 2004;13:452–460
  40. Kang JO , Hong SE . The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone . J Korean Med Sci . 2004;19:693–697
  41. Nam DH , Park K , Suh YL , et al.   Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma (Prognostic significance) . Oncol Rep . 2004;11:863–869
  42. Folkman J , Ingber D . Inhibition of angiogenesis . Semin Cancer Biol . 1992;3:89–96
  43. Tannock IF . Tumor physiology and drug resistance . Cancer Metast Rev . 2001;20:123–132
  44. Kuenen BC , Rosen L , Smit EF , et al.   Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors . J Clin Oncol . 2002;20:1657–1667
  45. Marx GM , Steer CB , Harper P , et al.   Unexpected serious toxicity with chemotherapy and antiangiogenic combinations (Time to take stock!) . J Clin Oncol . 2002;20:1446–1448
  46. Shipley WU , Stanley JA , Steel GG . Tumor size dependency in the radiation response of the Lewis lung carcinoma . Cancer Res . 1975;35:2488–2493
  47. Bergers G , Javaherian K , Lo KM , et al.   Effects of angiogenesis inhibitors on multistage carcinogenesis in mice . Science . 1999;284:808–812
  48. Folkman J . Angiogenesis-dependent diseases . Semin Oncol . 2001;28:536–542
  49. Folkman J . Role of angiogenesis in tumor growth and metastasis . Semin Oncol . 2002;29:15–18
  50. Carmeliet P , Jain RK . Angiogenesis in cancer and other diseases . Nature . 2000;407:249–257
  51. Cavallaro U , Christofori G . Molecular mechanisms of tumor angiogenesis and tumor progression . J Neurooncol . 2000;50:63–70
  52. Teicher BA , Sotomayor EA , Huang ZD . Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease . Cancer Res . 1992;52:6702–6704
  53. Dahut WL , Gulley JL , Arlen PM , et al.   Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer . J Clin Oncol . 2004;22:2532–2539
  54. Kabbinavar F , Hurwitz HI , Fehrenbacher L , et al.   Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer . J Clin Oncol . 2003;21:60–65
  55. Heymach JV , Desai J , Manola J , et al.   Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas . Clin Cancer Res . 2004;10:5732–5740
  56. Deplanque G , Madhusudan S , Jones PH , et al.   Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma . Br J Cancer . 2004;91:1645–1650
  57. Peterson AC , Swiger S , Stadler WM , et al.   Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma . Clin Cancer Res . 2004;10:4048–4054
  58. Stadler WM , Cao D , Vogelzang NJ , et al.   A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer . Clin Cancer Res . 2004;10:3365–3370
  59. Cao Y , O’Reilly MS , Marshall B , et al.   Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases . J Clin Invest . 1998;101:1055–1063
  60. Holmgren L , O’Reilly MS , Folkman J . Dormancy of micrometastases (Balanced proliferation and apoptosis in the presence of angiogenesis suppression) . Nat Med . 1995;1:149–153
  61. O’Reilly MS , Holmgren L , Shing Y , et al.   Angiostatin (A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma) . Cell . 1994;79:315–328
  62. Yamamoto A , Yano S , Shiraga M , et al.   A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice . Int J Cancer . 2003;103:822–828
  63. Mauceri HJ , Seetharam S , Beckett MA , et al.   Angiostatin potentiates cyclophosphamide treatment of metastatic disease . Cancer Chemother Pharmacol . 2002;50:412–418
  64. Klos KS , Zhou X , Lee S , et al.   Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone . Cancer . 2003;98:1377–1385
  65. Ning S , Laird D , Cherrington JM , et al.   The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation . Radiat Res . 2002;157:45–51
  66. Hess C , Vuong V , Hegyi I , et al.   Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth . Br J Cancer . 2001;85:2010–2016
  67. Dancey J , Sausville EA . Issues and progress with protein kinase inhibitors for cancer treatment . Nat Rev Drug Discov . 2003;2:296–313
  68. Rowinsky EK . Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies . J Clin Oncol . 2003;21:175–186
  69. Kerbel RS , Kamen BA . The anti-angiogenic basis of metronomic chemotherapy . Nat Rev Cancer . 2004;4:423–436
  70. Gasparini G . Metronomic scheduling (The future of chemotherapy?) . Lancet Oncol . 2001;2:733–740
  71. Browder T , Butterfield CE , Kraling BM , et al.   Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer . Cancer Res . 2000;60:1878–1886
  72. Sirotnak FM , Zakowski MF , Miller VA , et al.   Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase . Clin Cancer Res . 2000;6:4885–4892
  73. Bello L , Carrabba G , Giussani C , et al.   Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo . Cancer Res . 2001;61:7501–7506
  74. Kisker O , Becker CM , Prox D , et al.   Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model . Cancer Res . 2001;61:7669–7674
  75. Petrangolini G , Pratesi G , De Cesare M , et al.   Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts . Mol Cancer Res . 2003;1:863–870
  76. Ergun A , Camphausen K , Wein LM . Optimal scheduling of radiotherapy and angiogenic inhibitors . Bull Math Biol . 2003;65:407–424
  77. Hilmas DE , Gillette EL . Tumor microvasculature following fractionated X irradiation . Radiology . 1975;116:165–169
  78. Cooney MM , Tserng K-Y , Makar V , et al.   A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck . Cancer Chemother Pharmacol . 2005;55:295–300
  79. Lee C-K , Barlogie B , Munshi N , et al.   DTPACE (An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma) . J Clin Oncol . 2003;21:2732–2739
  80. Jansen M , de Witt Hamer PC , Witmer AN , et al.   Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas . Brain Res Brain Res Rev . 2004;45:143–163
  81. Burke PA , DeNardo SJ . Antiangiogenic agents and their promising potential in combined therapy . Crit Rev Oncol Hematol . 2001;39:155–171
  82. Bernsen HJ , Rijken PF , Oostendorp T , et al.   Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse . Br J Cancer . 1995;71:721–726
  83. Takada K , Yamada S , Teramoto A . Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas . Endocrin Pathol . 2004;15:131–139
  84. Tan G , Cioc AM , Perez-Montiel D , et al.   Microvascular density does not correlate with histopathology and outcome in neuroendocrine tumors of the pancreas . Appl Immunohistochem Mol Morphol . 2004;12:31–35
  85. Coskun U , Gunel N , Sancak B , et al.   Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients . Breast . 2003;12:104–110
  86. Sliutz G , Tempfer C , Obermair A , et al.   Serum evaluation of basic FGF in breast cancer patients . Anticancer Res . 1995;15:2675–2677
  87. Poon RT , Ho JW , Tong CS , et al.   Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma . Br J Surg . 2004;91:1354–1360
  88. Tamura M , Oda M , Matsumoto I , et al.   The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer . Ann Surg Oncol . 2004;11:928–933
  89. Tamura M , Oda M , Tsunezuka Y , et al.   Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer . Chest . 2004;126:342–346
  90. Li L , Wang L , Zhang W , et al.   Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer . Anticancer Res . 2004;24:1973–1979
  91. Alvarez Secord A , Sayer R , Snyder SA , et al.   The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer . Gynecol Oncol . 2004;94:74–79
  92. Kaya A , Ciledag A , Gulbay BE , et al.   The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients . Respir Med . 2004;98:632–636
  93. Braybrooke JP , O’Byrne KJ , Propper DJ , et al.   A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis . Clin Cancer Res . 2000;6:4697–4704
  94. Fine HA , Figg WD , Jaeckle K , et al.   Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas . J Clin Oncol . 2000;18:708–715
  95. Shimada H , Takeda A , Nabeya Y , et al.   Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma . Cancer . 2001;92:663–669
  96. Choi JH , Ahn MJ , Jang SJ , et al.   Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma . Int J Hematol . 2002;76:460–464
  97. Park SH , Lee SS . The relationship between serum VEGF concentration and prognosis of lung cancer . Korean J Intern Med . 2003;18:207–211
  98. Negrier S , Perol D , Menetrier-Caux C , et al.   Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma (Prognostic value of interleukin-6—from the Groupe Francais d’Immunotherapie) . J Clin Oncol . 2004;22:2371–2378
  99. Ribas C , Colleoni GW , Silva MR , et al.   Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma . Eur J Haematol . 2004;73:311–317
  100. Nieder C , Andratschke N , Jeremic B , et al.   Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer . Anticancer Res . 2003;23:5117–5123
  101. Chan LW , Moses MA , Goley E , et al.   Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy (A longitudinal study of protein kinetics throughout tumor progression and therapy) . J Clin Oncol . 2004;22:499–506
  102. Ria R , Portaluri M , Russo F , et al.   Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy . Cancer Lett . 2004;216:103–107
  103. Shimada H , Hoshino T , Okazumi S , et al.   Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma . Br J Cancer . 2002;86:552–557
  104. Kumar H , Heer K , Greenman J , et al.   Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients . Anticancer Res . 2002;22:1877–1880
  105. Bewick M , Conlon M , Lee H , et al.   Evaluation of sICAM-1, sVCAM-1, and sE-selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy . Stem Cells Dev . 2004;13:281–294
  106. Opala T , Drews K , Rzymski P , et al.   Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses . Eur J Gynaecol Oncol . 2003;24:255–257
  107. Pasieka Z , Stepien H , Komorowski J , et al.   Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer . Recent Results Cancer Res . 2003;162:189–194
  108. Boulbou MS , Koukoulis GN , Makri ED , et al.   Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension . Int J Cardiol . 2005;98:39–44
  109. Marz W , Scharnagl H , Winkler K , et al.   Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health study) . Circulation . 2004;110:3068–3074
  110. Mocco J , Choudhri TF , Mack WJ , et al.   Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis . Neurosurgery . 2001;48:718–721
  111. Littler AJ , Buckley CD , Wordsworth P , et al.   A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis . Br J Rheumatol . 1997;36:164–169
  112. Cush JJ , Rothlein R , Lindsley HB , et al.   Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis . Arthritis Rheum . 1993;36:1098–1102
  113. Ihn H , Fujimoto M , Sato S , et al.   Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma . J Am Acad Dermatol . 1994;31:591–595
  114. Nordal RA , Wong CS . Intercellular adhesion molecule-1 and blood-spinal cord barrier disruption in central nervous system radiation injury . J Neuropathol Exp Neurol . 2004;63:474–483
  115. Ishii Y , Kitamura S . Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis . Eur Respir J . 1999;13:733–738
  116. Davidoff AM , Ng CYC , Brown P , et al.   Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice . Clin Cancer Res . 2001;7:2870–2879
  117. Lyden D , Hattori K , Dias S , et al.   Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth . Nat Med . 2001;7:1194–1201
  118. Capillo M , Mancuso P , Gobbi A , et al.   Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors . Clin Cancer Res . 2003;9:377–382
  119. Shintani S , Murohara T , Ikeda H , et al.   Mobilization of endothelial progenitor cells in patients with acute myocardial infarction . Circulation . 2001;103:2776–2779
  120. Gill M , Dias S , Hattori K , et al.   Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells . Circ Res . 2001;88:167–174
  121. Rabascio C , Muratori E , Mancuso P , et al.   Assessing tumor angiogenesis (Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells) . Cancer Res . 2004;64:4373–4377
  122. Cosgrove D . Angiogenesis imaging—Ultrasound . Br J Radiol . 2003;76:S43–S49
  123. Forsberg F , Ro R , Potoczek M , et al.   Assessment of angiogenesis (implications for ultrasound imaging) . Ultrasonics . 2004;42:325–330
  124. Kothari M , Guermazi A , White D , et al.   Imaging in antiangiogenesis trial (A clinical trials radiology perspective) . Br J Radiol . 2003;76:S92–S96
  125. Schirner M , Menrad A , Stephens A , et al.   Molecular imaging of tumor angiogenesis . Ann NY Acad Sci . 2004;1014:67–75
  126. Padhani A . Dynamic contrast-enhanced MRI in clinical oncology (Current status and future directions) . J Magn Reson Imaging . 2002;16:407–422
  127. Choyke P , Dwyer A , Knopp M . Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging . J Magn Reson Imaging . 2003;17:509–520

PII: S0360-3016(05)00641-3

doi: 10.1016/j.ijrobp.2005.03.065

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 15-25 , 1 January 2006

Article Tools